For adults with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy (ERT) is not a therapeutic option (eg, due to allergy, hypersensitivity, or poor venous access)1
ZAVESCA® is a glucosylceramide synthase inhibitor indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 for whom ERT is not a therapeutic option (eg, due to allergy, hypersensitivity, or poor venous access).1
We remain dedicated to assisting the type 1 Gaucher disease community by:
- Helping patients get started on therapy through our specialty pharmacy, Accredo
- Educating about financial assistance programs which may be available to eligible patients
Accredo is a registered trademark of Accredo Health Group, Inc.
Reference:
References: 1. ZAVESCA® (miglustat) full Prescribing Information. Actelion Pharmaceuticals US, Inc.